His main fields of interest are targeted therapies, drug development, as well as thoracic and head & neck oncology.

Professor Syrigos has participated in several international phase I–IV clinical trials in lung, colon, head & neck, and pancreatic cancer. His research interests include neoangiogenesis and the role of adhesion molecules in the neovasculature.

He has published several papers on the role of the E-cadherin–catenin pathway in the pathogenesis, prognosis, and prediction of neoplastic diseases. He has also conducted early phase (I–II) clinical trials with agents targeting this pathway.